Application of chitosan modified nanocarriers in breast cancer

被引:49
作者
Dubey, Sunil Kumar [1 ,2 ]
Bhatt, Tanya [2 ]
Agrawal, Mukta [3 ]
Saha, Ranendra Narayan [2 ]
Saraf, Swarnlata [4 ]
Saraf, Shailendra [4 ]
Alexander, Amit [5 ]
机构
[1] Emami Ltd, Med Res, R&D Healthcare Div, 13 BT Rd, Kolkata 700056, India
[2] Pilani BITS PILANI, Dept Pharm, Birla Inst Technol & Sci, Pilani Campus, Pilani, Rajasthan, India
[3] SVKMs Narsee Monjee Inst Management Studies NMIMS, Sch Pharm & Technol Management, Hyderabad 509301, India
[4] Univ Inst Pharm, Pt Ravishankar Shukla Univ, Raipur 492010, Chhattisgarh, India
[5] Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Dept Pharmaceut, Gauhati 781101, Assam, India
关键词
Chitosan nanoparticles; Breast Cancer; Gemcitabine; Doxorubicin; Tamoxifen; Curcumin; DRUG-DELIVERY SYSTEM; MAGNETIC NANOPARTICLES; TARGETED DELIVERY; PHASE-II; IN-VITRO; THERAPEUTIC-EFFICACY; ANTICANCER EFFICACY; ANTITUMOR-ACTIVITY; CO-DELIVERY; DOXORUBICIN;
D O I
10.1016/j.ijbiomac.2021.11.095
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As per the WHO, every year around 2.1 million women are detected with breast cancer. It is one of the most invasive cancer in women and second most among all, contributing around 15% of death worldwide. The available anticancer therapies including chemo, radio, and hormone therapy are associated with a high load of reversible and irreversible adverse effects, limited therapeutic efficacy, and low chances of quality survival. To minimize the side effects, improving therapeutic potency and patient compliance promising targeted therapies are highly desirable. In this sequence, various nanocarriers and target modified systems have been explored by researchers throughout the world. Among these chitosan-based nanocarriers offers one of the most interesting, flexible, and biocompatible systems. The unique characteristics of chitosan like surface flexibility, biocompatibility, hydrophilicity, non-toxic and cost-effective behavior assist to overcome the inadequacy of existing therapy. The present review throws light on the successes, failures, and current status of chitosan modified novel techniques for tumor targeting of bioactives. It also emphasizes the molecular classification of breast cancer and current clinical development of novel therapies. The review compiles most relevant works of the past 10 years focusing on the application of chitosan-based nanocarrier against breast cancer.
引用
收藏
页码:521 / 538
页数:18
相关论文
共 158 条
[1]   A simple approach to design chitosan functionalized Fe3O4 nanoparticles for pH responsive delivery of doxorubicin for cancer therapy [J].
Adimoolam, Mahesh G. ;
Amreddy, Narsireddy ;
Nalam, Madhusudana Rao ;
Sunkara, Manorama V. .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2018, 448 :199-207
[2]   Stimuli-responsive In situ gelling system for nose-to-brain drug delivery [J].
Agrawal, Mukta ;
Saraf, Shailendra ;
Saraf, Swarnlata ;
Dubey, Sunil K. ;
Puri, Anu ;
Gupta, Umesh ;
Kesharwani, Prashant ;
Ravichandiran, V ;
Kumar, Pramod ;
Naidu, V. G. M. ;
Murty, Upadhyayula Suryanarayana ;
Ajazuddin ;
Alexander, Amit .
JOURNAL OF CONTROLLED RELEASE, 2020, 327 :235-265
[3]   Synthesis, characterization and in vitro studies of pegylated melphalan conjugates [J].
Ajazuddin ;
Alexander, Amit ;
Amarji, Basant ;
Kanaujia, Parijat .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2013, 39 (07) :1053-1062
[4]   Molecular classification of breast cancer: A retrospective cohort study [J].
Al-thoubaity, Fatma Khinaifis .
ANNALS OF MEDICINE AND SURGERY, 2020, 49 :44-48
[5]   Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate [J].
Alexander, Amit ;
Saraf, Swarnlata ;
Saraf, Shailendra .
CURRENT DRUG DELIVERY, 2016, 13 (04) :621-630
[6]   A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates [J].
Alexander, Amit ;
Saraf, Swarnlata ;
Saraf, Shailendra .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (12) :1954-1961
[7]   Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate [J].
Alexander, Amit ;
Ajazuddin ;
Khan, Junaid ;
Saraf, Swarnlata ;
Saraf, Shailendra .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2014, 66 (09) :1240-1250
[8]   Approaches for breaking the barriers of drug permeation through transdermal drug delivery [J].
Alexander, Amit ;
Dwivedi, Shubhangi ;
Ajazuddin ;
Giri, Tapan K. ;
Saraf, Swarnlata ;
Saraf, Shailendra ;
Tripathi, Dulal Krishna .
JOURNAL OF CONTROLLED RELEASE, 2012, 164 (01) :26-40
[9]   Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells [J].
Alinejad, Vahideh ;
Somi, Mohammad Hossein ;
Baradaran, Behzad ;
Akbarzadeh, Parvin ;
Atyabi, Fatemeh ;
Kazerooni, Hanif ;
Kafil, Hosein Samadi ;
Maleki, Leili Aghebati ;
Mansouri, Homayoon Siah ;
Yousefi, Mehdi .
BIOMEDICINE & PHARMACOTHERAPY, 2016, 83 :229-240
[10]   Molecular Pathology of Breast Cancer What a Pathologist Needs to Know [J].
Allison, Kimberly H. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (06) :770-780